Wedbush Reiterates Outperform on Viridian Therapeutics, Maintains $46 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has reiterated an Outperform rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a $46 price target.
September 13, 2023 | 1:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico has reiterated an Outperform rating on Viridian Therapeutics and maintained a $46 price target.
The reiteration of an Outperform rating and a maintained price target by a reputable analyst like Laura Chico from Wedbush is a positive signal for Viridian Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100